V-Co Investors 3 LLC Acquires 10% Stake in Vivos Therapeutics, Inc. via Private Placement

On March 31, 2026, V-Co Investors 3 LLC acquired 1,353,625 shares of Common Stock of Vivos Therapeutics, Inc. (VVOS) through a private placement. This acquisition represents a 10.0% ownership stake in the company. The transaction was part of a Securities Purchase Agreement that included a $2,390,000 subscription amount, partially funded through the conversion of a $1,400,000 convertible promissory note. In addition to the common stock, V-Co Investors 3 LLC received Series A and Series B warrants to purchase an additional 3,567,164 shares, and a pre-funded warrant for 429,957 shares, though exercise is limited by a 19.99% beneficial ownership blocker. The filing is part of a joint statement including V-CO Investors LLC, V-Co Investors 2 LLC, SP Manager LLC, and Michael C. Skaff. Collectively, the group may be deemed to beneficially own 2,696,123 shares, or 19.9% of the issuer. The reporting persons intend to engage with management regarding financial performance and strategic direction.